iBio, Inc. Common Stock Net Assets
iBio, Inc. Common Stock net assets. Based on the latest financial reports, iBio, Inc. Common Stock (IBIO) has net assets worth $85.71 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($99.11 Million) and total liabilities ($13.40 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore IBIO net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $85.71 Million |
| % of Total Assets | 86.48% |
| Annual Growth Rate | N/A |
| 5-Year Change | 35.01% |
| 10-Year Change | 861.45% |
| Growth Volatility | 856.87 |
Net Assets of iBio, Inc. Common Stock (2007–2026)
Net assets of iBio, Inc. Common Stock from 2007 to 2026. This chart illustrates how iBio, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See iBio, Inc. Common Stock (IBIO) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for iBio, Inc. Common Stock (2007–2026)
The table below shows the annual net assets of iBio, Inc. Common Stock from 2007 to 2026. For live market cap and overall valuation, see iBio, Inc. Common Stock (IBIO) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2026-06-30 | $85.71 Million | +476.03% |
| 2025-06-30 | $14.88 Million | -30.22% |
| 2024-06-30 | $21.32 Million | +38.64% |
| 2023-06-30 | $15.38 Million | -75.77% |
| 2022-06-30 | $63.48 Million | -41.53% |
| 2021-06-30 | $108.57 Million | +91.79% |
| 2020-06-30 | $56.61 Million | +2203.91% |
| 2019-06-30 | $2.46 Million | -84.80% |
| 2018-06-30 | $16.16 Million | +81.31% |
| 2017-06-30 | $8.91 Million | -62.92% |
| 2016-06-30 | $24.04 Million | +114.09% |
| 2015-06-30 | $11.23 Million | +84.14% |
| 2014-06-30 | $6.10 Million | +20.34% |
| 2013-06-30 | $5.07 Million | -17.85% |
| 2012-06-30 | $6.17 Million | +3037.19% |
| 2011-06-30 | $196.64K | -81.73% |
| 2010-06-30 | $1.08 Million | -75.48% |
| 2009-06-30 | $4.39 Million | +170.75% |
| 2008-06-30 | $-6.20 Million | -43.14% |
| 2007-06-30 | $-4.33 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to iBio, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 36035972300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
iBio, Inc. Common Stock Net Assets Breakdown (June 2026)
iBio, Inc. Common Stock net assets breakdown by equity component as of June 2026.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $56.00K | 0.07% |
| Other Comprehensive Income | $-45.00K | -0.05% |
| Other Components | $450.97 Million | 526.14% |
| Total Equity | $85.71 Million | 100.00% |
iBio, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of iBio, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Top Win International Limited
NASDAQ:SORA
|
$52.96 Million |
|
CONCORD ENVIRO SYSTEMS L
NSE:CEWATER
|
$52.97 Million |
|
Xin Chio Global Co Ltd
TWO:3171
|
$52.98 Million |
|
Yoong Onn Corporation Bhd
KLSE:5159
|
$52.98 Million |
|
Senzime AB
ST:SEZI
|
$52.96 Million |
|
Rock Tech Lithium Inc
V:RCK
|
$52.95 Million |
|
Iconic Worldwide Bhd
KLSE:9113
|
$52.95 Million |
|
THN Corporation
KO:019180
|
$52.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in iBio, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 14,880,000 to 85,713,000, a change of 70,833,000 (476.0%).
- Net loss of 33,044,000 reduced equity.
- New share issuances of 3,529,000 increased equity.
- Other comprehensive income decreased equity by 45,000.
- Other factors increased equity by 100,393,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-33.04 Million | -38.55% |
| Share Issuances | $3.53 Million | +4.12% |
| Other Comprehensive Income | $-45.00K | -0.05% |
| Other Changes | $100.39 Million | +117.13% |
| Total Change | $- | 476.03% |
Book Value vs Market Value Analysis
This analysis compares iBio, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-06-30 | $-23.09 | $0.82 | x |
| 2008-06-30 | $-33.05 | $0.82 | x |
| 2009-06-30 | $1082.71 | $0.82 | x |
| 2010-06-30 | $197.09 | $0.82 | x |
| 2011-06-30 | $31.75 | $0.82 | x |
| 2012-06-30 | $780.79 | $0.82 | x |
| 2013-06-30 | $513.16 | $0.82 | x |
| 2014-06-30 | $484.32 | $0.82 | x |
| 2015-06-30 | $785.44 | $0.82 | x |
| 2016-06-30 | $613.62 | $0.82 | x |
| 2017-06-30 | $500.17 | $0.82 | x |
| 2018-06-30 | $760.32 | $0.82 | x |
| 2019-06-30 | $65.07 | $0.82 | x |
| 2020-06-30 | $450.82 | $0.82 | x |
| 2021-06-30 | $277.54 | $0.82 | x |
| 2022-06-30 | $3639.78 | $0.82 | x |
| 2023-06-30 | $25.12 | $0.82 | x |
| 2024-06-30 | $5.57 | $0.82 | x |
| 2025-06-30 | $1.42 | $0.82 | x |
| 2026-06-30 | $0.82 | $0.82 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently iBio, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -38.55%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -33044.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.16x
- Recent ROE (-38.55%) is above the historical average (-439.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 0.00% | -185.88% | 0.24x | 0.00x | $-1.23 Million |
| 2008 | 0.00% | -189.35% | 0.28x | 0.00x | $-1.25 Million |
| 2009 | -43.46% | -162.02% | 0.24x | 1.12x | $-2.35 Million |
| 2010 | -564.80% | -22511.11% | 0.01x | 4.58x | $-6.19 Million |
| 2011 | -6174.67% | -2334.64% | 0.07x | 37.31x | $-12.16 Million |
| 2012 | -92.01% | -444.48% | 0.13x | 1.58x | $-6.29 Million |
| 2013 | -122.30% | -615.49% | 0.11x | 1.85x | $-6.70 Million |
| 2014 | -60.11% | -1788.29% | 0.03x | 1.06x | $-4.28 Million |
| 2015 | -58.99% | -357.91% | 0.15x | 1.11x | $-7.75 Million |
| 2016 | -98.26% | -1029.96% | 0.02x | 5.19x | $-10.76 Million |
| 2017 | -163.02% | -3688.32% | 0.01x | 4.04x | $-15.42 Million |
| 2018 | -99.62% | -3627.25% | 0.01x | 2.67x | $-17.72 Million |
| 2019 | -714.29% | -871.80% | 0.07x | 12.42x | $-17.84 Million |
| 2020 | -29.03% | -1003.60% | 0.02x | 1.66x | $-22.10 Million |
| 2021 | -21.37% | -978.79% | 0.02x | 1.35x | $-34.07 Million |
| 2022 | -79.37% | -2674.68% | 0.02x | 1.57x | $-56.74 Million |
| 2023 | -190.57% | -58622.00% | 0.00x | 2.68x | $-30.85 Million |
| 2024 | -116.80% | -11069.78% | 0.01x | 1.35x | $-27.04 Million |
| 2025 | -123.50% | -4594.25% | 0.02x | 1.56x | $-19.86 Million |
| 2026 | -38.55% | -33044.00% | 0.00x | 1.16x | $-41.62 Million |
Industry Comparison
This section compares iBio, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| iBio, Inc. Common Stock (IBIO) | $85.71 Million | 0.00% | 0.16x | $52.96 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About iBio, Inc. Common Stock
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimiz… Read more